| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 1.1K | 5.9% |
| Total Income | 1.1K | 6.2% |
| Expenditure | 998.01 | 6.9% |
| PBT | 121.94 | 18.1% |
| Net Profit | 105.59 | 23.3% |
| OPM | 18.73% | 2.73pp |
| NPM | 9.36% | 2.24pp |
| EPS | 10.81 | 21.2% |
Strides Pharma Science Ltd Reports Q1 FY 2026 with Rs. 11,197 Million Revenue and Rs. 1,140 Million Operational PAT
29 Jul 2025 · 29 Jul 2025, 12:43 pm
Summary
Strides Pharma Science Ltd has reported its Q1 FY 2026 results with a revenue of Rs. 11,197 Million and Rs. 1,140 Million Operational PAT. The company's EBITDA grew by 14.8% YoY to Rs. 2,181 Million with an EBITDA margin at 19.5%. The operational EPS stands at 12.4.
Key Highlights
- 1
Revenue at Rs. 11,197 Million, grew 6.2% YoY
- 2
Absolute gross margin at Rs. 6,755 Million, grew 11.7% YoY
- 3
Gross margin improved to 60.3%, up 300bps YoY
- 4
EBITDA grew 14.8% YoY to Rs. 2,181 Million with EBITDA margin at 19.5%, grew 150bps YoY
- 5
US revenue at $71m, grew 7.0% YoY
- 6
Operational PAT at Rs. 1,140 Million, Grew 80.6% YoY
- 7
Operational EPS at 12.4
- 8
ROCE stands at 15.1% for Q1
Management Comments
Badree Komandur
MD & Group CEO
We are pleased to report a solid start to the year, marked by consistent growth and enhanced profitability. Our focus on cost management and diligent execution has enabled us to deliver robust results. The EBITDA margin improved to 19.5%, an increase of 150bps YoY. Strong operating leverage contributed to the highest-ever quarterly PAT, resulting in an operational EPS of 12.4. Consequently, ROCE stands at 15.1% for Q1. The company will enhance its R&D efforts during the year to drive sustainable long-term growth.
Informational and educational content only. Not investment advice.